The global market for Peptide Drug CDMO was valued at US$ 2571 million in the year 2023 and is projected to reach a revised size of US$ 4911 million by 2030, growing at a CAGR of 10.1% during the forecast period.
Peptide CDMO refers to an organization that accepts commissions from pharmaceutical companies and engages in the development and production of peptide drugs. These organizations usually have advanced peptide synthesis, purification, analysis and other technologies, and can provide customers with one-stop services from peptide API synthesis, purification, structural identification to formulation development, clinical trials, etc.
As a unique drug compound, peptides are between small molecules and proteins, and are different in biochemistry and treatment. Peptides provide opportunities for therapeutic interventions that closely mimic natural pathways and play a major role in various physiological processes in the human body (including hormones, neurotransmitters) or in inflammatory responses. Peptide drugs have the characteristics of strong selectivity and rapid onset, and can be extracted naturally or synthesized artificially. With multiple advantages such as high purity and controllable quality, they have become popular drugs at present. The medical field is an important application market for peptide substances, and the market demand for peptide drugs is increasing. Based on the complexity and high-tech characteristics of peptide drug development, peptide development and production outsourcing services came into being, that is, peptide CDMO began to appear.
North American market for Peptide Drug CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Peptide Drug CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Peptide Drug CDMO in Antineoplastic Drugs is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Peptide Drug CDMO include Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Peptide Drug CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Drug CDMO.
The Peptide Drug CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Drug CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide Drug CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Segment by Type
APIs and Intermediates
FDF
Segment by Application
Antineoplastic Drugs
Geno-Urinary System and Sex Hormones
Cardiovascular System Drugs
Anti-Infective Drugs
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Drug CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Peptide Drug CDMO 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 麻豆原创 by Application
1.3.1 Global Peptide Drug CDMO 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Antineoplastic Drugs
1.3.3 Geno-Urinary System and Sex Hormones
1.3.4 Cardiovascular System Drugs
1.3.5 Anti-Infective Drugs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide Drug CDMO 麻豆原创 Perspective (2019-2030)
2.2 Global Peptide Drug CDMO Growth Trends by Region
2.2.1 Global Peptide Drug CDMO 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Peptide Drug CDMO Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Peptide Drug CDMO Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Peptide Drug CDMO 麻豆原创 Dynamics
2.3.1 Peptide Drug CDMO Industry Trends
2.3.2 Peptide Drug CDMO 麻豆原创 Drivers
2.3.3 Peptide Drug CDMO 麻豆原创 Challenges
2.3.4 Peptide Drug CDMO 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide Drug CDMO Players by Revenue
3.1.1 Global Top Peptide Drug CDMO Players by Revenue (2019-2024)
3.1.2 Global Peptide Drug CDMO Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Peptide Drug CDMO 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide Drug CDMO Revenue
3.4 Global Peptide Drug CDMO 麻豆原创 Concentration Ratio
3.4.1 Global Peptide Drug CDMO 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Drug CDMO Revenue in 2023
3.5 Global Key Players of Peptide Drug CDMO Head office and Area Served
3.6 Global Key Players of Peptide Drug CDMO, Product and Application
3.7 Global Key Players of Peptide Drug CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide Drug CDMO Breakdown Data by Type
4.1 Global Peptide Drug CDMO Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Peptide Drug CDMO Forecasted 麻豆原创 Size by Type (2025-2030)
5 Peptide Drug CDMO Breakdown Data by Application
5.1 Global Peptide Drug CDMO Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Peptide Drug CDMO Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Peptide Drug CDMO 麻豆原创 Size (2019-2030)
6.2 North America Peptide Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Peptide Drug CDMO 麻豆原创 Size by Country (2019-2024)
6.4 North America Peptide Drug CDMO 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide Drug CDMO 麻豆原创 Size (2019-2030)
7.2 Europe Peptide Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Peptide Drug CDMO 麻豆原创 Size by Country (2019-2024)
7.4 Europe Peptide Drug CDMO 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide Drug CDMO 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Peptide Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Peptide Drug CDMO 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Peptide Drug CDMO 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide Drug CDMO 麻豆原创 Size (2019-2030)
9.2 Latin America Peptide Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Peptide Drug CDMO 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Peptide Drug CDMO 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide Drug CDMO 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Peptide Drug CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Peptide Drug CDMO 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Peptide Drug CDMO 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Peptide Drug CDMO Introduction
11.1.4 Bachem Revenue in Peptide Drug CDMO Business (2019-2024)
11.1.5 Bachem Recent Development
11.2 PolyPeptide
11.2.1 PolyPeptide Company Details
11.2.2 PolyPeptide Business Overview
11.2.3 PolyPeptide Peptide Drug CDMO Introduction
11.2.4 PolyPeptide Revenue in Peptide Drug CDMO Business (2019-2024)
11.2.5 PolyPeptide Recent Development
11.3 CordenPharma
11.3.1 CordenPharma Company Details
11.3.2 CordenPharma Business Overview
11.3.3 CordenPharma Peptide Drug CDMO Introduction
11.3.4 CordenPharma Revenue in Peptide Drug CDMO Business (2019-2024)
11.3.5 CordenPharma Recent Development
11.4 AmbioPharm
11.4.1 AmbioPharm Company Details
11.4.2 AmbioPharm Business Overview
11.4.3 AmbioPharm Peptide Drug CDMO Introduction
11.4.4 AmbioPharm Revenue in Peptide Drug CDMO Business (2019-2024)
11.4.5 AmbioPharm Recent Development
11.5 USV Peptides
11.5.1 USV Peptides Company Details
11.5.2 USV Peptides Business Overview
11.5.3 USV Peptides Peptide Drug CDMO Introduction
11.5.4 USV Peptides Revenue in Peptide Drug CDMO Business (2019-2024)
11.5.5 USV Peptides Recent Development
11.6 Thermofischer
11.6.1 Thermofischer Company Details
11.6.2 Thermofischer Business Overview
11.6.3 Thermofischer Peptide Drug CDMO Introduction
11.6.4 Thermofischer Revenue in Peptide Drug CDMO Business (2019-2024)
11.6.5 Thermofischer Recent Development
11.7 Bio Basic
11.7.1 Bio Basic Company Details
11.7.2 Bio Basic Business Overview
11.7.3 Bio Basic Peptide Drug CDMO Introduction
11.7.4 Bio Basic Revenue in Peptide Drug CDMO Business (2019-2024)
11.7.5 Bio Basic Recent Development
11.8 JPT
11.8.1 JPT Company Details
11.8.2 JPT Business Overview
11.8.3 JPT Peptide Drug CDMO Introduction
11.8.4 JPT Revenue in Peptide Drug CDMO Business (2019-2024)
11.8.5 JPT Recent Development
11.9 Genscript
11.9.1 Genscript Company Details
11.9.2 Genscript Business Overview
11.9.3 Genscript Peptide Drug CDMO Introduction
11.9.4 Genscript Revenue in Peptide Drug CDMO Business (2019-2024)
11.9.5 Genscript Recent Development
11.10 Xinbang Pharma
11.10.1 Xinbang Pharma Company Details
11.10.2 Xinbang Pharma Business Overview
11.10.3 Xinbang Pharma Peptide Drug CDMO Introduction
11.10.4 Xinbang Pharma Revenue in Peptide Drug CDMO Business (2019-2024)
11.10.5 Xinbang Pharma Recent Development
11.11 ScinoPharm
11.11.1 ScinoPharm Company Details
11.11.2 ScinoPharm Business Overview
11.11.3 ScinoPharm Peptide Drug CDMO Introduction
11.11.4 ScinoPharm Revenue in Peptide Drug CDMO Business (2019-2024)
11.11.5 ScinoPharm Recent Development
11.12 SN Biopharm
11.12.1 SN Biopharm Company Details
11.12.2 SN Biopharm Business Overview
11.12.3 SN Biopharm Peptide Drug CDMO Introduction
11.12.4 SN Biopharm Revenue in Peptide Drug CDMO Business (2019-2024)
11.12.5 SN Biopharm Recent Development
11.13 CBL
11.13.1 CBL Company Details
11.13.2 CBL Business Overview
11.13.3 CBL Peptide Drug CDMO Introduction
11.13.4 CBL Revenue in Peptide Drug CDMO Business (2019-2024)
11.13.5 CBL Recent Development
11.14 Piramal Pharma
11.14.1 Piramal Pharma Company Details
11.14.2 Piramal Pharma Business Overview
11.14.3 Piramal Pharma Peptide Drug CDMO Introduction
11.14.4 Piramal Pharma Revenue in Peptide Drug CDMO Business (2019-2024)
11.14.5 Piramal Pharma Recent Development
11.15 CPC Scientific
11.15.1 CPC Scientific Company Details
11.15.2 CPC Scientific Business Overview
11.15.3 CPC Scientific Peptide Drug CDMO Introduction
11.15.4 CPC Scientific Revenue in Peptide Drug CDMO Business (2019-2024)
11.15.5 CPC Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
听
听
*If Applicable.
